These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 28768921)

  • 1. Efficacy and Safety of the Cholesteryl Ester Transfer Protein Inhibitor Evacetrapib in Combination With Atorvastatin in Japanese Patients With Primary Hypercholesterolemia.
    Teramoto T; Kiyosue A; Iimura T; Takita Y; Riesmeyer JS; Murakami M
    Circ J; 2017 Dec; 82(1):183-191. PubMed ID: 28768921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Cholesteryl Ester Transfer Protein Inhibitor Evacetrapib Administered as Monotherapy in Japanese Patients With Primary Hypercholesterolemia.
    Teramoto T; Kiyosue A; Iimura T; Takita Y; Riesmeyer JS; Murakami M
    Circ J; 2017 Oct; 81(11):1686-1692. PubMed ID: 28652529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, safety, tolerability, and pharmacokinetic profile of evacetrapib administered as monotherapy or in combination with atorvastatin in Japanese patients with dyslipidemia.
    Teramoto T; Takeuchi M; Morisaki Y; Ruotolo G; Krueger KA
    Am J Cardiol; 2014 Jun; 113(12):2021-9. PubMed ID: 24786356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.
    Nicholls SJ; Brewer HB; Kastelein JJ; Krueger KA; Wang MD; Shao M; Hu B; McErlean E; Nissen SE
    JAMA; 2011 Nov; 306(19):2099-109. PubMed ID: 22089718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial.
    Nicholls SJ; Ray KK; Ballantyne CM; Beacham LA; Miller DL; Ruotolo G; Nissen SE; Riesmeyer JS;
    Atherosclerosis; 2017 Jun; 261():12-18. PubMed ID: 28412650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological Inhibition of CETP (Cholesteryl Ester Transfer Protein) Increases HDL (High-Density Lipoprotein) That Contains ApoC3 and Other HDL Subspecies Associated With Higher Risk of Coronary Heart Disease.
    Furtado JD; Ruotolo G; Nicholls SJ; Dullea R; Carvajal-Gonzalez S; Sacks FM
    Arterioscler Thromb Vasc Biol; 2022 Feb; 42(2):227-237. PubMed ID: 34937388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease.
    Lincoff AM; Nicholls SJ; Riesmeyer JS; Barter PJ; Brewer HB; Fox KAA; Gibson CM; Granger C; Menon V; Montalescot G; Rader D; Tall AR; McErlean E; Wolski K; Ruotolo G; Vangerow B; Weerakkody G; Goodman SG; Conde D; McGuire DK; Nicolau JC; Leiva-Pons JL; Pesant Y; Li W; Kandath D; Kouz S; Tahirkheli N; Mason D; Nissen SE;
    N Engl J Med; 2017 May; 376(20):1933-1942. PubMed ID: 28514624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of the cholesteryl ester transfer protein inhibitor evacetrapib on lipoproteins, apolipoproteins and 24-h ambulatory blood pressure in healthy adults.
    Suico JG; Wang MD; Friedrich S; Cannady EA; Konkoy CS; Ruotolo G; Krueger KA
    J Pharm Pharmacol; 2014 Nov; 66(11):1576-85. PubMed ID: 24961753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of CETP inhibition with evacetrapib in patients with diabetes mellitus enrolled in the ACCELERATE trial.
    Menon V; Kumar A; Patel DR; St John J; Riesmeyer J; Weerakkody G; Ruotolo G; Wolski KE; McErlean E; Cremer PC; Nicholls SJ; Lincoff AM; Nissen SE
    BMJ Open Diabetes Res Care; 2020 Mar; 8(1):. PubMed ID: 32179516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with heterozygous familial hypercholesterolemia.
    Arai H; Teramoto T; Daida H; Ikewaki K; Maeda Y; Nakagomi M; Shirakawa M; Kakikawa T; Numaguchi H; Johnson-Levonas AO; Vaidya S; Blaustein RO
    Atherosclerosis; 2016 Jun; 249():215-23. PubMed ID: 27131642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Evacetrapib for Modifying Plasma Lipids: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Sahebkar A; Simental-Mendía LE; Guerrero-Romero F; Golledge J; Watts GF
    Curr Pharm Des; 2016; 22(5):595-608. PubMed ID: 26601964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin.
    McKenney JM; Davidson MH; Shear CL; Revkin JH
    J Am Coll Cardiol; 2006 Nov; 48(9):1782-90. PubMed ID: 17084250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholesterol Efflux Capacity and Pre-Beta-1 HDL Concentrations Are Increased in Dyslipidemic Patients Treated With Evacetrapib.
    Nicholls SJ; Ruotolo G; Brewer HB; Kane JP; Wang MD; Krueger KA; Adelman SJ; Nissen SE; Rader DJ
    J Am Coll Cardiol; 2015 Nov; 66(20):2201-2210. PubMed ID: 26564598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients.
    Bloomfield D; Carlson GL; Sapre A; Tribble D; McKenney JM; Littlejohn TW; Sisk CM; Mitchel Y; Pasternak RC
    Am Heart J; 2009 Feb; 157(2):352-360.e2. PubMed ID: 19185645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial.
    Nicholls SJ; Lincoff AM; Barter PJ; Brewer HB; Fox KA; Gibson CM; Grainger C; Menon V; Montalescot G; Rader D; Tall AR; McErlean E; Riesmeyer J; Vangerow B; Ruotolo G; Weerakkody GJ; Nissen SE
    Am Heart J; 2015 Dec; 170(6):1061-9. PubMed ID: 26678626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
    Stein E; Stender S; Mata P; Sager P; Ponsonnet D; Melani L; Lipka L; Suresh R; Maccubbin D; Veltri E;
    Am Heart J; 2004 Sep; 148(3):447-55. PubMed ID: 15389231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study.
    Ballantyne CM; Abate N; Yuan Z; King TR; Palmisano J
    Am Heart J; 2005 Mar; 149(3):464-73. PubMed ID: 15864235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial.
    Hovingh GK; Kastelein JJ; van Deventer SJ; Round P; Ford J; Saleheen D; Rader DJ; Brewer HB; Barter PJ
    Lancet; 2015 Aug; 386(9992):452-60. PubMed ID: 26047975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evacetrapib alone or in combination with statins lowers lipoprotein(a) and total and small LDL particle concentrations in mildly hypercholesterolemic patients.
    Nicholls SJ; Ruotolo G; Brewer HB; Wang MD; Liu L; Willey MB; Deeg MA; Krueger KA; Nissen SE
    J Clin Lipidol; 2016; 10(3):519-527.e4. PubMed ID: 27206939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.